CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 28 enrolled
Drug / intervention
ACALABRUTINIB +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05583149
NCT05583149Phase 2Active
CompareCT.gov

A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

Patrick C. Johnson, MD·interventional·Posted Oct 17, 2022·Updated Jan 29, 2026

In Brief

A Phase 2 clinical trial evaluating ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, and 1 other intervention for Refractory Aggressive B-cell Lymphomas and 12 related conditions. Active but no longer recruiting, targeting 28 participants across 2 sites.

Detailed Summary

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2Active
2023202420252026202720282029
First PostedOct 17, 2022
Enrollment StartMar 1, 2023
Primary CompletionNov 23, 2024
Study CompletionMar 1, 2029
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.7 years ago

Interventions

ACALABRUTINIBdrug

Oral, twice daily, timing and dosage per protocol

LISOCABTAGENE MARALEUCELdrug

via IV timings and dosage per protocol

Lymphodepleting chemotherapydrug

lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.